Профиль Critical Outcome Technologies Inc Registered Shs
Cotinga Pharmaceuticals, Inc. is engaged in the development of therapeutics for the treatment of cancer and other unmet medical needs. It offers COTI-2 and COTI-219 pipelines. The COTI-2 pipeline targets gynecologic cancers and head and neck squamous cell carcinoma. The COTI-219 pipeline focuses on the treatment of lung, colorectal, pancreatic and thyroid cancers. The company was founded on October 13, 2006 and is headquartered in Toronto, Canada.